OptimizeRx Launches CopayCue™, a Next-Generation Copay Activation Solution Powered by Real-Time Prescribing Intent
OptimizeRx has launched CopayCue™, a new solution designed to increase the transparency of brand savings offers for physicians within the e-prescribing workflow. This technology uses real-time HCP prescribing intent data to deliver copay card and affordability information, aiming to overcome medication affordability barriers and improve patient access to prescribed therapies. OptimizeRx states that CopayCue™ can increase prescription lift and overall program utilization by engaging healthcare professionals at critical prescribing moments.
OptimizeRx Launches CopayCue™, a Next-Generation Copay Activation Solution Powered by Real-Time Prescribing Intent
OptimizeRx has launched CopayCue™, an enhanced copay activation solution that integrates brand savings offers directly into the e-prescribing workflow for healthcare professionals. This technology uses real-time prescribing intent data to address medication affordability challenges, aiming to increase prescription fill rates and improve patient access to therapies by enabling timely delivery of financial assistance information. OptimizeRx emphasizes that CopayCue will help life sciences companies strengthen campaign performance and reduce missed opportunities at the point of conversion.
OptimizeRx stock rises after launching CopayCue product
OptimizeRx Corp (NASDAQ:OPRX) shares rose after the company announced the launch of CopayCue, a new product designed to deliver brand savings offers directly within healthcare professionals' prescribing workflows. This technology aims to address medication affordability issues, which contribute to common problems like patients not taking prescribed medications due to cost and unfilled prescriptions for new drugs. CopayCue leverages real-time prescribing data to send savings offers, such as copay cards, to pharmacies, and has shown to increase prescription fill rates.
OptimizeRx Corporation (OPRX) Stock Price | Live Quotes & Charts | NASDAQ
This article provides live stock quotes and charts for OptimizeRx Corporation (OPRX), detailing its current stock price, daily change, and percentage change. It notes the absence of recent analyst ratings and earnings information. The content also features promotional material for a stock trading bootcamp and free trade alerts.
OptimizeRx stock rises after launching CopayCue product By Investing.com
OptimizeRx Corp (NASDAQ:OPRX) shares rose after the company announced the launch of CopayCue, a new technology designed to deliver brand savings offers within the prescribing workflow. CopayCue aims to address medication affordability issues by providing copay cards and affordability resources when a healthcare professional intends to prescribe a specific therapy. The company stated that CopayCue has shown a 4-5% increase in prescription lift and enables life sciences organizations to engage healthcare professionals at critical prescribing moments.
OptimizeRx launches CopayCue for prescription savings
OptimizeRx Corp. has launched CopayCue, a new technology designed to deliver prescription savings offers directly to physicians during the prescribing process, aiming to improve medication affordability and patient access. The solution has shown a significant increase in prescription lift and operates within OptimizeRx's network of electronic health record and e-prescribing platforms. Despite recent strong quarterly earnings, the company revised its annual revenue guidance downwards due to customer-specific issues and economic uncertainties.
OptimizeRx Launches CopayCue™, a Next-Generation Copay Activation Solution Powered by Real-Time Prescribing Intent
OptimizeRx (Nasdaq: OPRX) has launched CopayCue™, a new solution designed to make brand savings offers more transparent to physicians at the point of prescribing. This enhancement to their Financial Assistance solution uses real-time HCP prescribing intent data to deliver copay cards and affordability resources directly within the e-prescribing workflow. The company states that CopayCue aims to overcome affordability barriers, increase prescription adherence, and improve the return on investment for life sciences companies' financial support programs.
OptimizeRx ties copay offers to physician intent at prescribing moment
OptimizeRx (Nasdaq: OPRX) has launched CopayCue, a new solution that delivers brand savings offers directly within e-prescribing workflows by leveraging real-time healthcare professional (HCP) prescribing intent data. This aims to overcome medication affordability barriers, which lead to significant non-adherence and substantial costs to the U.S. health system. CopayCue has shown promising results, increasing prescription lift by 4-5% over EHR banners and 11.5% in standalone programs, engaging 900,000 authenticated HCPs through a network of over 400 EHR/e-prescribing platforms.
Stifel reiterates Buy on OptimizeRX stock, cites AI tool launch By Investing.com
Stifel maintained a Buy rating and $14.00 price target on OptimizeRX (NASDAQ: OPRX) after the company launched an AI-powered tool called Natural Language Audience Builder. Despite recent stock decline, InvestingPro analysis suggests the company is undervalued and analysts expect profitability this year. The new tool aims to help pharmaceutical marketers build custom healthcare provider audiences, with integrations expected to generate new recurring revenue streams.
OptimizeRx stock rating maintained at Market Outperform by Citizens
Citizens has maintained a Market Outperform rating on OptimizeRx (NASDAQ: OPRX) with a $9.00 price target, indicating a 77% upside from its current trading price despite a recent 58% decline. The firm highlighted OptimizeRx's undervalued status according to InvestingPro analysis and noted significant upsell opportunities within its current biopharma client base, particularly as the company advances its digital prescribing strategy. OptimizeRx recently exceeded Q1 2026 earnings and revenue forecasts, though Stifel lowered its price target due to annual revenue guidance challenges.
OptimizeRx Corporation(NasdaqCM: OPRX) dropped from Russell 2000 Dynamic Index
OptimizeRx Corporation (NasdaqCM: OPRX) has been removed from the Russell 2000 Dynamic Index, as reported on MarketScreener. This announcement follows several recent company updates, including a change in its Chief Commercial Officer role and integration of its EHR network into an advertising platform. Analysts maintain a "Buy" rating for OptimizeRx, with varying price targets.
OptimizeRx Launches Natural Language Audience Builder for Life Sciences DSPs and Agency Media Planning Platforms
OptimizeRx has launched a Natural Language Audience Builder aimed at enhancing audience precision for life sciences digital signal processors (DSPs) and agency media planning platforms. This new tool leverages AI and deep learning to identify and refine healthcare professional (HCP) audiences, improving campaign effectiveness by allowing for highly specific targeting based on medical conditions and clinical attributes. It integrates with existing demand-side platforms to streamline the process of reaching relevant HCPs.
Citizens reiterates Market Outperform on OptimizeRX stock at forum By Investing.com
Citizens has reiterated a "Market Outperform" rating and a $9.00 price target for OptimizeRx (NASDAQ: OPRX) stock, despite the stock trading near its 52-week low. InvestingPro analysis suggests the company is undervalued, with a P/E ratio of 13.44 and a 16% free cash flow yield. The company recently reported better-than-expected Q1 2026 earnings but lowered its annual revenue guidance due to customer-specific issues and economic uncertainty.
OptimizeRx Launches Natural Language Audience Builder for Life Sciences DSPs and Agency Media Planning Platforms
OptimizeRx has launched its patent-pending Natural Language Audience Builder (NLAB), an AI-powered tool designed for life sciences DSPs and agency media planning platforms. NLAB uses real-world evidence and proprietary EHR network data to help marketers create custom HCP audiences using natural language prompts. This technology aims to enable more precise targeting and engagement with healthcare providers within existing media planning and buying workflows.
OptimizeRx puts HCP audience building inside ad-buying platforms
OptimizeRx (Nasdaq: OPRX) has launched its Natural Language Audience Builder (NLAB), an AI-powered tool that allows life sciences companies and agencies to build, refine, and activate custom healthcare provider (HCP) audiences using natural-language prompts. This patent-pending technology integrates real-world evidence with OptimizeRx’s EHR network and will be embeddable within demand-side platforms (DSPs) and agency media planning platforms starting August 2026. NLAB aims to streamline the process of identifying and engaging the right HCPs within existing media buying workflows, providing new recurring revenue streams for OptimizeRx and improving differentiated value for its partners.
Citizens reiterates Market Outperform on OptimizeRX stock at forum
Citizens reiterated a Market Outperform rating and $9.00 price target on OptimizeRx (NASDAQ:OPRX) shares, despite the stock trading near its 52-week low after a 63% decline in six months. The firm is hosting its annual Healthcare Services Forum where OptimizeRX will present, alongside NRC Health and Healthstream. This reiteration comes after OptimizeRx reported strong Q1 2026 earnings but lowered its annual revenue guidance due to customer-specific issues and economic uncertainty.
OptimizeRx Launches Natural Language Audience Builder for Life Sciences DSPs and Agency Media Planning Platforms
OptimizeRx has launched its patent-pending Natural Language Audience Builder (NLAB), an AI-powered tool designed for life sciences DSPs and agency media planning platforms. This technology enables marketers to create custom, verified HCP audiences using natural language prompts and proprietary data from OptimizeRx's EHR network. NLAB aims to streamline the audience-building process for healthcare marketers and enhance the value DSPs can offer to pharma and agency clients by integrating audience intelligence directly into workflows.
OptimizeRx Corp (OPRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of OptimizeRx Corp (OPRX), focusing on its price momentum, support and resistance levels, and various technical indicators and moving averages. The stock currently has a price momentum score of 6.55 and is trading between a resistance level of $5.49 and a support level of $4.42, suggesting suitability for range-bound swing trading. Technical indicators show mixed signals, with some recommending "Buy" and others "Sell" or "Neutral," while moving averages present an equal number of buy and sell signals.
OptimizeRx Corp (OPRX) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of OptimizeRx Corp (OPRX), highlighting its current valuation score of 8.20 within the Software & IT Services industry. It notes the company's current P/E ratio of 12.67, comparing it to recent highs and lows. The analysis also indicates that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
OptimizeRx Corp (OPRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for OptimizeRx Corp (OPRX), detailing its stock performance, market capitalization, and P/E ratio. It notes that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. The page serves as a placeholder for financial analysis for OPRX, indicating that more detailed revenue information is pending.
OptimizeRx Corp (OPRX) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of OptimizeRx Corp's (OPRX) dividend and stock split history. It notes that the company has distributed $0.00 in dividends over the past five years and shows no record of stock splits. The page also presents current stock performance data, including market cap and P/E ratio, and general company information.
OptimizeRx Corp (OPRX) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of OptimizeRx Corp (OPRX), listing its major individual and institutional holders, their proportion of shares, and recent changes in holdings. It also provides a breakdown of shareholder types by investment category and historical institutional shareholding data over several quarters.
OptimizeRx Corp (OPRX) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for OptimizeRx Corp (OPRX), highlighting its current risk score of 4.19 within the Software & IT Services industry. The company's beta of 1.14 suggests it is more volatile than the S&P 500. The assessment includes detailed metrics on volatility, maximum drawdown, and daily returns over various periods.
OptimizeRx Corp (OPRX) Earnings Forecast: Future EPS & Revenue Growth Estimates
OptimizeRx Corp (OPRX) currently holds an earnings forecast score of 8.67, ranking it 26th in the Software & IT Services industry. Analysts project an average price target of $24.00, with a consensus "Buy" rating based on 6 analyst reports. The company's next expected revenue is $20.20M, and the EPS for the upcoming quarter is anticipated to be $0.13.
OptimizeRx Corp (OPRX) Institutional Confidence
OptimizeRx Corp (OPRX) has an institutional shareholding score of 7.00, placing it 140th out of 489 in the Software & IT Services industry. Institutional investors hold 82.46% of shares, an increase of 8.32% quarter-over-quarter. The largest institutional shareholder is Bill Nygren (OAKMX), holding 1.14 million shares, representing 4.73% of outstanding shares.
OptimizeRx (OPRX) director awarded 17,258 restricted stock units in Form 4 filing
OptimizeRx Corp director Presti Mariyamma Varghese was granted 17,258 restricted stock units (RSUs) of common stock, increasing her direct holdings to 30,318 shares. This award was provided at no cash cost per unit and signifies a contingent right to receive shares. The RSUs will vest in full on the earlier of the first anniversary of the grant date or the company's next annual meeting of shareholders.
OptimizeRx (NASDAQ: OPRX) holders add 1M plan shares, reject evergreen
OptimizeRx shareholders approved an amendment to the 2021 Equity Incentive Plan, increasing the shares available for awards by 1,000,000 to a total of 5,450,000. While all director nominees were elected and executive compensation was approved on an advisory basis, a proposal to add an evergreen provision to the equity plan was rejected. Shareholders also ratified Grant Thornton LLP as the independent auditor for the fiscal year ending December 31, 2026.
OPRX SEC Filings - Optimizerx Corp 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Optimizerx (OPRX) SEC filings, including 10-K, 10-Q, 8-K forms, and insider trading reports. Recent filings detail equity awards for executives Edward Stelmakh, Theresa Greco, and Doug Besch, an amended employment letter for Brendan Merrell, Q2 2025 financial results showing strong revenue growth, and CEO Stephen Silvestro's appointment to the board. The platform offers AI-generated summaries, impact scoring, and sentiment analysis for each filing.
MissionIRNewsBreaks – OptimizeRx Corp. (NASDAQ: OPRX) Secures $35 Million Senior Credit Facility
OptimizeRx Corp. (NASDAQ: OPRX), a healthcare technology solutions provider, announced it has secured a $35 million senior secured credit facility with Fifth Third Bank. The facility includes a $25 million term loan and a $10 million revolving credit facility. Roth Capital Partners advised on the transaction, which aims to support OptimizeRx's mission of connecting life science brands with patients and healthcare providers through AI-driven platforms.
[Form 4] OptimizeRx Corp Insider Trading Activity
OptimizeRx Corp director Ellen O'Connor Vos reported an acquisition of 34,517 shares of common stock in the form of restricted stock units (RSUs) through a Form 4 filing. This award, granted as compensation, increases her direct holdings to 107,159 common shares. The RSUs will vest fully on the first anniversary of the grant date or the company's next annual meeting of shareholders, aligning her interests with future company performance.
[Form 4] OptimizeRx Corp Insider Trading Activity
A Form 4 filing reveals insider trading activity at OptimizeRx Corp (OPRX), specifically a grant of 34,517 shares of common stock to insider KLEMA CATHY. The filing indicates a "Neutral" impact and sentiment. The granted restricted stock units will vest on the earlier of the first anniversary of the grant date or the company's next annual meeting of shareholders.
OptimizeRx Corp stock: Q1 earnings beat lifted shares
OptimizeRx Corp (OPRX) reported a strong first quarter in 2026, with an EPS of $0.14 and revenue of $19.8 million, significantly exceeding analyst estimates. This performance led to a 2.42% rise in the stock price and highlights the company's success in the digital healthcare engagement sector. Investors are now looking to see if this positive execution and revenue growth can be sustained in future quarters as the company operates in the US healthcare commercialization market.
OptimizeRx parts ways with Theresa Greco; will serve as advisor through June 15, 2027
OptimizeRx (OPRX) and Theresa Greco have agreed to a separation, with Greco stepping down as Chief Commercial Officer on June 15, 2026. She will then transition to an advisory role through June 15, 2027, with her equity continuing to vest during this period. The reason for the separation was previously disclosed in a 10-Q filing.
OptimizeRx (NASDAQ: OPRX) details CCO exit, $380K salary continuation
OptimizeRx (NASDAQ: OPRX) announced that its Chief Commercial Officer, Theresa Greco, will transition from her role effective June 15, 2026, to serve as an advisor for 12 months. As part of a separation agreement, she will receive her $380,000 annual base salary for 12 months, a $209,000 annual bonus target payment, and 12 months of COBRA premium reimbursement. During her advisory period, her equity will continue to vest, and she will be subject to non-compete and non-solicitation clauses.
OptimizeRx to Participate in Upcoming Investor Conferences
OptimizeRx Corp. (Nasdaq: OPRX) announced its participation in two upcoming investor conferences in June 2026: the Stifel 2026 Boston Cross Sector 1x1 Conference and the 46th Annual William Blair Growth Stock Conference. Management will engage in 1x1 meetings at both events, with an additional corporate presentation scheduled for the William Blair conference. These events provide an opportunity for OptimizeRx, a healthcare technology company, to connect with investors and discuss its AI-driven solutions for life sciences brands.
Where to meet OptimizeRx: investor 1x1s in Boston and Chicago
OptimizeRx (Nasdaq: OPRX) announced its management will participate in two upcoming investor conferences in June 2026. Executives will attend the Stifel 2026 Boston Cross Sector 1x1 Conference on June 2, 2026, and William Blair’s 46th Annual Growth Stock Conference on June 3, 2026, in Chicago, where they will conduct 1x1 meetings and a corporate presentation. Investors interested in meeting with OptimizeRx management should contact their institutional representatives for more details and scheduling.
OptimizeRx to Participate in Upcoming Investor Conferences
OptimizeRx Corp. (Nasdaq: OPRX) announced its participation in two upcoming investor conferences: the Stifel 2026 Boston Cross Sector 1x1 Conference and the 46th Annual William Blair Growth Stock Conference. Management will engage in 1x1 meetings at both events, and will deliver a corporate presentation at the William Blair conference. These engagements aim to connect OptimizeRx, a leading healthcare technology company using AI for life science brands, with investors.
OptimizeRx vs. Doximity: Which Digital Health Stock Is the Better Bet?
This article compares OptimizeRx (OPRX) and Doximity (DOCS), two digital health companies, to determine which offers a better investment opportunity. Both companies operate in digital healthcare engagement, integrating AI tools and facing challenges like cautious pharmaceutical spending. The analysis delves into their fundamentals, growth prospects, market challenges, and valuations, ultimately concluding that Doximity (DOCS) appears to be a better option based on Zacks Rank, despite both facing downward estimate revisions and stock declines.
OptimizeRx Stock Down 30% in a Month: Should Investors Hold or Fold?
OptimizeRx (OPRX) stock has fallen 30% over the past month due to macroeconomic challenges, "most favored nation" pricing dynamics, and customer-specific execution issues, leading to reduced revenue guidance. Despite these headwinds, the company showed improved profitability through cost optimization and strong momentum in its AI-enabled DAAP platform, alongside strategic platform expansion and debt refinancing. Investors are advised to stay on the sidelines until the company demonstrates more stable growth and improved business momentum, as reflected by its Zacks Rank #4 (Sell).
DeepIntent Becomes First Healthcare DSP to Integrate OptimizeRx’s Authenticated EHR Network
DeepIntent, a leading healthcare demand-side platform (DSP), is integrating OptimizeRx’s proprietary electronic health record (EHR) network, making it the first DSP to do so. This collaboration aims to provide life sciences marketers with an easier and privacy-safe way to activate advertising within healthcare provider (HCP) workflows, leveraging programmatic tools. The integration, expected in Q3 2026, will expand access to point-of-care inventory, allowing marketers to reach providers closer to clinical decision moments and deliver timely, relevant information to support informed care decisions and improved patient outcomes.
OPRX Boosts DSP Revenue Potential While Navigating Near-Term Headwinds
This article discusses how OPRX is increasing its DSP revenue potential. It also touches on the company's efforts to navigate various near-term challenges.
OptimizeRx Stock Down 30% in a Month: Should Investors Hold or Fold?
OptimizeRx (OPRX) stock has fallen 30.4% in the last month, underperforming industry benchmarks and competitors due to macroeconomic challenges and changing customer spending habits. The company lowered its 2026 revenue guidance, citing limited visibility and a decline in contracted revenue. Despite these headwinds, OptimizeRx improved profitability metrics in Q1, with adjusted EBITDA more than doubling due to cost optimization and growth in its AI-enabled DAAP platform and subscription services, while also strengthening its long-term outlook through strategic platform expansion and improved financial flexibility.
OptimizeRx Stock Down 30% in a Month: Should Investors Hold or Fold?
OptimizeRx stock has fallen 30% in the past month, underperforming its industry and the S&P 500. The company faces challenges including macroeconomic pressures, cautious customer spending, and customer-specific execution issues, leading to a downward revision of its 2026 revenue guidance. Despite these headwinds, OptimizeRx improved profitability through cost optimization and is seeing momentum in its AI-enabled platform and subscription offerings, but its current Zacks Rank is a "Sell."
OptimizeRx Stock Down 30% in a Month: Should Investors Hold or Fold?
OptimizeRx stock has fallen 30% over the past month due to macroeconomic challenges and disruption from "most favored nation" pricing dynamics, leading to cautious customer spending and reduced contract durations. Despite a decline in revenue and operating cash flow, the company showed improved profitability in Q1 through cost optimization and growth in its AI-enabled DAAP platform. However, given ongoing revenue visibility issues and customer disruptions, investors are advised to stay on the sidelines.
OptimizeRx Corp stock (US6837631027): earnings momentum and buyback plan put focus back on digital h
OptimizeRx Corp (OPRX) recently reported better-than-expected quarterly earnings and announced a new share buyback program, bringing renewed attention to the digital health company. The company surpassed consensus estimates with EPS of $0.14 and revenue of $19.84 million. OptimizeRx operates a digital health network connecting pharmaceutical manufacturers, payers, and healthcare providers, leveraging its platform-based model to integrate with EHR systems and monetize access for life sciences companies.
OptimizeRx (OPRX) CCO logs Form 4 tax-withholding share dispositions
OptimizeRx Chief Commercial Officer Theresa Greco reported routine tax-related share dispositions via two Form 4 filings. On May 15, 2026, the company withheld 879 and 914 shares of Common Stock at $5.21 per share to cover her tax obligations upon the vesting of restricted stock units. These transactions, totaling 1,793 shares, are not open-market sales but standard equity-compensation tax treatments, leaving Greco with over 71,000 shares.
OptimizeRx (OPRX) CEO has 5,219 shares withheld to cover RSU tax
OptimizeRx CEO Stephen L. Silvestro had 5,219 shares of common stock withheld by the company on May 15, 2026, to cover tax withholding obligations related to the vesting of restricted stock units. This transaction, valued at $5.21 per share, is considered a disposition under Section 16 rules but was not an open-market sale. After this, Silvestro directly owned 185,288 shares of OptimizeRx common stock.
OptimizeRx's Q4 Beat: A Closer Look at the Numbers
OptimizeRx (OPRX) reported strong Q4 and full-year 2025 financial results, exceeding estimates with record net income and adjusted EBITDA. However, the company's cautious 2026 guidance, citing a shift away from managed services and client spending conservatism due to MFN pricing uncertainties, led to a significant stock sell-off. Despite near-term challenges, OptimizeRx is strategically poised to leverage long-term digital health trends, including AI and the booming specialty medication market, particularly GLP-1s, presenting a potential long-term opportunity for patient investors.
OptimizeRx (Nasdaq:OPRX) - Stock Analysis
This Simply Wall St report provides a detailed analysis of OptimizeRx (OPRX), highlighting its current stock performance, valuation metrics, and recent news. The company is trading significantly below its estimated fair value, with analysts forecasting strong earnings growth, despite recent volatility in its share price. Recent updates include revised earnings guidance, new product launches, and changes to its board and executive team.
OptimizeRx Corp stock (US6837631027): earnings beat, buyback plan and volatile AI-health rally
OptimizeRx Corp (OPRX) reported stronger-than-expected Q1 2026 earnings and announced a $10 million stock buyback program, despite its shares having fallen more than 50% year-to-date. The company, focused on AI-powered digital health solutions, aims to leverage its technology to connect pharmaceutical manufacturers with healthcare providers through electronic health records. Analysts maintain a "Moderate Buy" rating, with an average price target of $13.43, reflecting both confidence in its growth potential and recognition of execution risks in a volatile market for small-cap technology stocks.
